Raadpleeg ook literatuurlijsten gerandomiseerde studies van niet-toxische middelen en behandelingen van arts-bioloog drs. Engelbert Valstar waarin melatonine veelvuldig wordt genoemd.

Zie ook deze search op het woord melatonine op onze website.
Zie ook in gerelateerde artikelen

17 februari 2020: Bron: Springerlink

Melatonine verminderde het risico op depressieve symptomen bij vrouwen met borstkanker  gedurende een periode van drie maanden na een operatie van borstkanker aanzienlijk. Blijkt uit een gerandomiseerde placebo gecontroleerde studie.

De Deense onderzoekers onderzochten of melatonine het risico op depressieve symptomen bij vrouwen met borstkanker kon verlagen in een periode van drie maanden na de operatie en beoordeelden het effect van melatonine op de volgende subjectieve parameters: angst, slaap, algemeen welzijn, vermoeidheid, pijn en slaperigheid.

Vrouwen, 30-75 jaar, die een operatie ondergingen voor borstkanker en zonder tekenen van depressie op Major Depression Inventory (MDI) werden 1 week voor de operatie opgenomen en ontvingen 6 mg orale melatonine of placebo gedurende 3 maanden. De primaire uitkomst was de incidentie van depressieve symptomen gemeten met MDI.

54 borstkankerpatiënten werden gerandomiseerd ingedeeld in melatonineroep (n = 28) of placebogroep (n = 26).
11 patiënten trokken zich terug uit de studie (10 uit de placebogroep en 1 uit de melatoninegroep, P = 0,002).

Het risico op het ontwikkelen van depressieve symptomen was significant lager met melatonine dan met placebo (3 van 27 patiënten [11%] versus 9 van 20 patienten [45%] ; relatief risico 0,25 [95% BI 0,077-0,80]), met een NNT van 3,0 [95% BI 1,7-11,0]. 

Uit een andere gerandomiseerde studie blijkt dat het gebruik van melatonine voor en tijdens de eerste cyclus van chemo na operatie van borstkanker duidelijk de pijn vermindert en beter dan placebo minder hoge pijnscores geeft beoordeeld door veranderingen in de 0–10 Numerical Pain Scale (NPS).

Multivariabele analyses van covariabelen laat zien dat melatonine de functie van het DPMS verbeterde. Het mediane gemiddelde (SD) op de NPS (0-10) tijdens de CPM-taak in de placebogroep was −1,91 [−1,81 (1,67) versus −0,1 (1,61)], en in de melatoninegroep was −3,5 [−0,94 (1,61) versus −2,29 (1,61)], en het gemiddelde verschil (md) tussen behandelingsgroepen was 1,59 [(95% BI, 0,50 tot 2,68).

Van de studie: The Effects of Melatonin on the Descending Pain Inhibitory System and Neural Plasticity Markers in Breast Cancer Patients Receiving Chemotherapy: Randomized, Double-Blinded, Placebo-Controlled Trial is het volledige studierapport vrij in te zien.

Van de studie Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: a randomized, double-blind, placebo-controlled trial is alleen het abstract vrij in te zien.

Hier de twee abstracten:

These results suggest that oral melatonin, together with the first ACBC counteracts the dysfunction in the inhibitory DPMS and improves pain perception measures. Also, it shows that changes in the neuroplasticity state mediate the impact of melatonin on pain.

. 2019; 10: 1382.
Published online 2019 Nov 22. doi: 10.3389/fphar.2019.01382
PMCID: PMC6883914
PMID: 31824318

The Effects of Melatonin on the Descending Pain Inhibitory System and Neural Plasticity Markers in Breast Cancer Patients Receiving Chemotherapy: Randomized, Double-Blinded, Placebo-Controlled Trial

Abstract

Background: Adjuvant chemotherapy for breast cancer (ACBC) has been associated with fatigue, pain, depressive symptoms, and disturbed sleep. And, previous studies in non-cancer patients showed that melatonin could improve the descending pain modulatory system (DPMS). We tested the hypothesis that melatonin use before and during the first cycle of ACBC is better than placebo at improving the DPMS function assessed by changes in the 0–10 Numerical Pain Scale (NPS) during the conditioned pain modulating task (CPM-task) (primary outcome). The effects of melatonin were evaluated in the following secondary endpoints: heat pain threshold (HPT), heat pain tolerance (HPTo), and neuroplasticity state assessed by serum brain-derived neurotrophic factor (BDNF), tropomyosin kinase receptor B, and S100B-protein and whether melatonin’s effects on pain and neuroplasticity state are due more so to its impact on sleep quality.

Methods: Thirty-six women, ages 18 to 75 years old, scheduled for their first cycle of ACBC were randomized to receive 20mg of oral melatonin (n = 18) or placebo (n = 18). The effect of treatment on the outcomes was analyzed by delta (Δ)-values (from pre to treatment end).

Results: Multivariate analyses of covariance revealed that melatonin improved the function of the DPMS. The Δ-mean (SD) on the NPS (0–10) during the CPM-task in the placebo group was −1.91 [−1.81 (1.67) vs. −0.1 (1.61)], and in the melatonin group was −3.5 [−0.94 (1.61) vs. −2.29 (1.61)], and the mean difference (md) between treatment groups was 1.59 [(95% CI, 0.50 to 2.68). Melatonin’s effect increased the HPTo and HPT while reducing the (Δ)-means of the serum neuroplasticity marker in placebo vs. melatonin. The Δ-BDNF is 1.87 (7.17) vs. −20.44 (17.17), respectively, and the md = 22.31 [(95% CI = 13.40 to 31.22)]; TrKB md = 0.61 [0.46 (0.17) vs. −0.15 (0.18); 95% CI = 0.49 to 0.73)] and S00B-protein md = −8.27[(2.89 (11.18) vs. −11.16 (9.75); 95% CI = −15.38 to −1.16)]. However, melatonin’s effect on pain and the neuroplastic state are not due to its effect on sleep quality.

Conclusions: These results suggest that oral melatonin, together with the first ACBC counteracts the dysfunction in the inhibitory DPMS and improves pain perception measures. Also, it shows that changes in the neuroplasticity state mediate the impact of melatonin on pain.

Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT03205033

Melatonin significantly reduced the risk of depressive symptoms in women with breast cancer during a three-month period after surgery.

 2014 Jun;145(3):683-95. doi: 10.1007/s10549-014-2962-2. Epub 2014 Apr 23.

Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: a randomized, double-blind, placebo-controlled trial.

Author information

1
Department of Surgery, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, 2730, Herlev, Denmark, melis_vh@hotmail.com.

Abstract

Depression, anxiety and sleep disturbances are known problems in patients with breast cancer. The effect of melatonin as an antidepressant in humans with cancer has not been investigated. We investigated whether melatonin could lower the risk of depressive symptoms in women with breast cancer in a three-month period after surgery and assessed the effect of melatonin on subjective parameters: anxiety, sleep, general well-being, fatigue, pain and sleepiness. Randomized, double-blind, placebo-controlled trial undertaken from July 2011 to December 2012 at a department of breast surgery in Copenhagen, Denmark. Women, 30-75 years, undergoing surgery for breast cancer and without signs of depression on Major Depression Inventory (MDI) were included 1 week before surgery and received 6 mg oral melatonin or placebo for 3 months. The primary outcome was the incidence of depressive symptoms measured by MDI. The secondary outcomes were area under the curve (AUC) for the subjective parameters. 54 patients were randomized to melatonin (n = 28) or placebo (n = 26) and 11 withdrew from the study (10 placebo group and 1 melatonin group, P = 0.002). The risk of developing depressive symptoms was significantly lower with melatonin than with placebo (3 [11 %] of 27 vs. 9 [45 %] of 20; relative risk 0.25 [95 % CI 0.077-0.80]), giving a NNT of 3.0 [95 % CI 1.7-11.0]. No significant differences were found between AUC for the subjective parameters. No differences in side effects were found (P = 0.78). Melatonin significantly reduced the risk of depressive symptoms in women with breast cancer during a three-month period after surgery.

PMID:
 
24756186
 
DOI:
 
10.1007/s10549-014-2962-2

Referentielijst melatonine studies

References

  • Affleck G., Urrows S., Tennen H., Higgins P., Abeles M. (1996). Sequential daily relations of sleep, pain intensity, and attention to pain among women with fibromyalgiaPain 68 (2–3), 363–368. 10.1016/S0304-3959(96)03226-5 [PubMed] [CrossRef[]
  • Ananth C., Gopalakrishnakone P., Kaur C. (2003). Protective role of melatonin in domoic acid-induced neuronal damage in the hippocampus of adult ratsHippocampus 13, 375–387. 10.1002/hipo.10090 [PubMed] [CrossRef[]
  • Boland E. G., Selvarajah D., Hunter M., Ezaydi Y., Tesfaye S., Ahmedzai S. H., et al. (2014). Central pain processing in chronic chemotherapy- induced peripheral neuropathy?: a functional magnetic resonance imaging studyPLoS ONE 9 (5), e96474. 10.1371/journal.pone.0096474 [PMC free article] [PubMed] [CrossRef[]
  • Botelho L. M., Morales-Quezada L., Rozisky J. R., Brietzke A. P., Torres I. L. S., Deitos A., et al. (2016). A framework for understanding the relationship between descending pain modulation, motor corticospinal, and neuroplasticity regulation systems in chronic myofascial painFront. Hum. Neurosci. 10 (308), 1–12. 10.3389/fnhum.2016.00308 [PMC free article] [PubMed] [CrossRef[]
  • Bower J. E., Ganz P. A., Irwin M. R., Kwan L., Breen E. C., Cole S. W. (2011). Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism?J. Clin. Oncol. 29 (26), 3517–3522. 10.1200/JCO.2011.36.1154 [PMC free article] [PubMed] [CrossRef[]
  • Brietzke A. P., Antunes L. C., Carvalho F., Elkifury J., Gasparin A., Sanches P. R. S., et al. (2019). Potency of descending pain modulatory system is linked with peripheral sensory dysfunction in fibromyalgia: An exploratory studyMedicine (Baltimore) 98 (3), e13477. 10.1097/MD.0000000000013477 [PMC free article] [PubMed] [CrossRef[]
  • Brzezinski A. (1997). Melatonin in humansN. Engl. J. Med. 336, 186–95. 10.1056/NEJM199701163360306 [PubMed] [CrossRef[]
  • Carvalho F., Pedrazzoli M., Gasparin A., Zortea M., Souza A., Torres I. L. S., et al. (2019). PER3 variable number tandem repeat (VNTR) polymorphism modulates the circadian variation of the descending pain modulatory system in healthy subjectsSci. Rep. 9 (1), 9363. 10.1038/s41598-019-45527-y [PMC free article] [PubMed] [CrossRef[]
  • Caumo W., Antunes L. C., Elkfury J. L., Herbstrith E. G., Sipmann R. B., Souza A., et al. (2017). The central sensitization inventory validated and adapted for a Brazilian population: Psychometric properties and its relationship with brain-derived neurotrophic factorJ. Pain Res. 10, 2109–2122. 10.2147/JPR.S131479 [PMC free article] [PubMed] [CrossRef[]
  • Chaves M. L., Camozzato A. L., Ferreira E. D., Piazenski I., Kochhann R., Dall'igna O., et al. (2010). Serum levels of S100B and NSE in Alzheimer's disease patientsJ. Neuroinflammation 7 (1), 6. 10.1186/1742-2094-7-6 [PMC free article] [PubMed] [CrossRef[]
  • de Zanette S. A., Vercelino R., Laste G., Rozisky J. R., Schwertner A., Machado C. B., et al. (2014). Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trialBMC Pharmacol. Toxicol. 2315, 40. 10.1186/2050-6511-15-40 [PMC free article] [PubMed] [CrossRef[]
  • Donato R R., Cannon B., Sorci G., Riuzzi F., Hsu K., Weber D J., et al. (2013). Functions of S100 ProteinsCurr. Mol. Med. 13 (1), 24–57. 10.2174/156652413804486214 [PMC free article] [PubMed] [CrossRef[]
  • Donato R. (2001). S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional rolesInt. J. Biochem. Cell Biol. 33 (7), 637–668. 10.1016/S1357-2725(01)00046-2 [PubMed] [CrossRef[]
  • Eversley R., Estrin D., Dibble S., Wardlaw L., Pedrosa M., Favila-Penney W. (2005). Post-treatment symptoms among ethnic minority breast cancer survivorsOncol. Nurs. Forum. 32 (2), 250–256. 10.1188/05.ONF.250-256 [PubMed] [CrossRef[]
  • Ghilardi J. R., Freeman K. T., Jimenez-Andrade J. M., Mantyh W. G., Bloom A. P., Kuskowski M. A., et al. (2010). Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer painMol. Pain 6, 1–12. 10.1186/1744-8069-6-87 [PMC free article] [PubMed] [CrossRef[]
  • Given C. W., Given B., Azzouz F., Kozachik S., Stommel M. (2001). Predictors of pain and fatigue in the year following diagnosis among elderly cancer patientsJ. Pain Symptom Manage. 21 (6), 456–466. 10.1016/S0885-3924(01)00284-6 [PubMed] [CrossRef[]
  • Gonçalves C. A., Concli Leite M., Nardin P. (2008). Biological and methodological features of the measurement of S100B, a putative marker of brain injuryClin. Biochem. 41 (10–11), 755–763. 10.1016/j.clinbiochem.2008.04.003 [PubMed] [CrossRef[]
  • Grilli M., Memo M. (1999). Nuclear factor-?B/Rel proteins: a point of convergence of signalling pathways relevant in neuronal function and dysfunctionBiochem. Pharmacol. 57 (1), 1–7. 10.1016/S0006-2952(98)00214-7 [PubMed] [CrossRef[]
  • Ichesco E., Puiu T., Hampson J., Kairys A., Clauw D., Harte S., et al. (2016). Altered fMRI resting-state connectivity in individuals with fibromyalgia on acute pain stimulationEur. J. Pain 20, 1079–1089. 10.1002/ejp.832 [PubMed] [CrossRef[]
  • Innominato P. F., Lim A. S., Palesh O. et al. (2016). The effect of melatonin on sleep and quality of life in patients with advanced breast cancerSupport Care Cancer 24 (3), 1097–1105. 10.1007/s00520-015-2883-6 [PubMed] [CrossRef[]
  • Jang M. H., Jung S. B., Lee M. H., Kim C. J., Oh Y. T., Kang I., et al. (2005). Melatonin attenuates amyloid beta25-35-induced apoptosis in mouse microglial BV2 cellsNeurosci. Lett. 380 (1-2), 26–31. 10.1016/j.neulet.2005.01.003 [PubMed] [CrossRef[]
  • Jing Y. L., Wu Q. B., Yuan X. C., Li B. W., Liu M. M., Zhang X. Y., et al. (2014). Microvascular protective role of pericytes in melatonin-treated spinal cord injury in the C57BL/6 miceChin. Med. J. (Engl) 127 (15), 2808–2813. 10.3760/cma.j.issn.0366-6999.20140858 [PubMed] [CrossRef[]
  • Jumnongprakhon P., Govitrapong P., Tocharus C., Pinkaew D., Tocharus J. (2015). Melatonin protects methamphetamine-induced neuroinflammation through nf-?b and nrf2 pathways in glioma cell lineNeurochem. Res. 40 (7), 1448–1456. 10.1007/s11064-015-1613-2 [PubMed] [CrossRef[]
  • Kaila-Kangas L., Kivimäki M., Härmä M., Riihimäki H., Luukkonen R., Kirjonen J., et al. (2006). Sleep disturbances as predictors of hospitalization for back disorders-a 28-year follow-up of industrial employeesSpine 31 (1), 51–56. 10.1097/01.brs.0000193902.45315.e5 (Phila Pa 1976). [PubMed] [CrossRef[]
  • Kaltschmidt B., Widera D., Kaltschmidt C. (2005). Signaling via NF-?B in the nervous systemBiochim. Biophys. Acta-Mol. Cell Res. 1745 (3), 287–299. 10.1016/j.bbamcr.2005.05.009 [PubMed] [CrossRef[]
  • Karege F., Schwald M., Cisse M. (2002). Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and plateletsNeurosci. Lett. 328 (3), 261–264. 10.1016/S0304-3940(02)00529-3 [PubMed] [CrossRef[]
  • Lévi F. (2006). Chronotherapeutics: the relevance of timing in cancer therapyCancer Causes Control 17 (4), 611–621. 10.1007/s10552-005-9004-7 [PubMed] [CrossRef[]
  • Lee E., Lee M., Chen H., Hsu Y., Wu T., Chen S., et al. (2005). Melatonin attenuates gray and white matter damage in a mouse model of transient focal cerebral ischemiaJ. Pineal Res. 38, 42–52. 10.1111/j.1600-079X.2004.00173.x [PubMed] [CrossRef[]
  • Leknes S., Berna C., Lee M. C., Snyder G. D., Biele G., Tracey I. (2013). The importance of context: when relative relief renders pain pleasantPain 154 (3), 402–410. 10.1016/j.pain.2012.11.018 [PMC free article] [PubMed] [CrossRef[]
  • Lezoualc F., Sparapani M. (1998). N-acetj BC. N-acetyl-serotonin (normelatonin) and melatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF-kappaBJ. Pineal Res. 168–178. 10.1111/j.1600-079X.1998.tb00530.x [PubMed] [CrossRef[]
  • Lopez H. P., Dreher R. A., Bissette G., Karolewicz B., Shaffery J. P. (2008). Rapid eye movement sleep deprivation decreases long-term potentiation stability and affects some glutamatergic signaling proteins during hippocampal developmentNeuroscience 153 (1), 44–53. 10.1016/j.neuroscience.2008.01.072 [PMC free article] [PubMed] [CrossRef[]
  • Lopez-Canul M., Comai S., Gobbi G. (2015. a). Antinociceptive properties of selective MT(2) melatonin receptor partial agonistsEuropean Journal Pharmacology. 764, 424–432. 10.1016/j.ejphar.2015.07.010 [PubMed] [CrossRef[]
  • Lopez-Canul M., Palazzo E., Dominguez-Lopez S., Luongo L., Lacoste B., Comai S., et al. (2015. b). Selective melatonin MT2 receptor ligands relieve neuropathic pain through modulation of brainstem descending antinociceptive pathwaysPain 156 (2), 305–317. 10.1097/01.j.pain.0000460311.71572.5f [PubMed] [CrossRef[]
  • Macleod M. R., O'Collins T., Horky L. L., Howells D. W., Donnan G. A. (2005). Systematic review and meta-analysis of the efficacy of melatonin in experimental strokeJ. Pineal. Res. 38 (1), 35–41. 10.1111/j.1600-079X.2004.00172.x [PubMed] [CrossRef[]
  • Malek R., Borowicz K. K., Jargiello M., Czuczwar S. J. (2007). Role of nuclear factor kappaB in the central nervous systemPharmacol. Rep. 59 (1), 25–33. [PubMed[]
  • Manchester L. C., Coto-Montes A., Boga J. A., Andersen L. P. H., Zhou Z., Galano A., et al. (2015). Melatonin: An ancient molecule that makes oxygen metabolically tolerableJ Pineal Res 59 (4), 403–419. 10.1111/jpi.12267 [PubMed] [CrossRef[]
  • Marchi N., Rasmussen P., Kapural M., et al. (2003). Peripheral markers of brain damage and blood-brain barrier dysfunctionRestor. Neurol. Neurosci. 21 (3–4), 109–121. PMC4066375 [PMC free article] [PubMed[]
  • Oglodek E. A., Marek J., Just A. R., Szromek A. A. (2016). Melatonin and neurotrophins NT-3, BDNF, NGF in patients with varying levels of depression severityPharmacological Reports. 68 (5), 945–951. 10.1016/j.pharep.2016.04.003 [PubMed] [CrossRef[]
  • Ong W. Y., Stohler C. S., Herr D. R. (2019). Role of the Prefrontal Cortex in Pain ProcessingMol. Neurobiol. 56 (2), 1137–1166. 10.1007/s12035-018-1130-9 [PMC free article] [PubMed] [CrossRef[]
  • Purabdollah M., Lakdizaji S., Rahmani A. (2017). Relationship between Sleep, Pain and Inflammatory Markers in Patients with Rheumatoid ArthritisJ Caring Sci. 6 (3), 249–255. 10.15171/jcs.2017.024 [PMC free article] [PubMed] [CrossRef[]
  • Rasmussen C. L., Klee Olsen M., Thit Johnsen A., Aagaard Petersen M., Lindholm H., Andersen L., et al. (2015). Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: A double-blind placebo-controlled crossover trialCancer 121 (20), 3727–3736. 10.1002/cncr.29563 [PubMed] [CrossRef[]
  • Reiter R. J., Tan D. X., Kim S. J., Cruz M. H. C. (2014). Delivery of pineal melatonin to the brain and SCN: role of canaliculi, cerebrospinal fluid, tanycytes and Virchow-Robin perivascular spacesBrain Struct. Funct. 219 (6), 1873–1887. 10.1007/s00429-014-0719-7 [PubMed] [CrossRef[]
  • Ren K., Dubner R. (2007). Pain facilitation and activity-dependent plasticity in pain modulatory circuitry: Role of BDNF-TrkB signaling and NMDA receptorsMol. Neurobiol. 35 (3), 224–235. 10.1007/s12035-007-0028-8 [PubMed] [CrossRef[]
  • Rief W., Bardwell W. A., Dimsdale J. E., Natarajan L., Flatt S. W., Pierce J. P. (2011). Long-term course of pain in breast cancer survivors: a 4-year longitudinal studyBreast Cancer Res. Treat. 130 (2), 579–586. 10.1007/s10549-011-1614-z [PMC free article] [PubMed] [CrossRef[]
  • Roehrs T., Roth T. (2005). Sleep and pain: Interaction of two vital functionsSemin. Neurol. 25 (1), 106–116. 10.1055/s-2005-867079 [PubMed] [CrossRef[]
  • Schestatsky P., Cadore S. L., Roberto S. P., Pereira da S. J. D., Silva T. I. L., Letizzia D. A., et al. (2011). Validation of a Brazilian quantitative sensory testing (QST) device for the diagnosis of small fiber neuropathiesArq. Neuro-Psiquiatr. 69 (6), 943–948. 10.1590/S0004-282X2011000700019 [PubMed] [CrossRef[]
  • Schwertner A., Conceição Dos Santos C. C., Costa G. D., Deitos A., De Souza A., De Souza I. C. C., et al. (2013). Efficacy of melatonin in the treatment of endometriosis: A phase II, randomized, double-blind, placebo-controlled trialPain 154 (6), 874–881. 10.1016/j.pain.2013.02.025 [PubMed] [CrossRef[]
  • Seely D., Wu P., Fritz H., Kennedy D. A., Tsui T., Seely A. J. E., et al. (2012). Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trialsIntegr. Cancer Ther 11 (4), 293–303. 10.1177/1534735411425484 [PubMed] [CrossRef[]
  • Serikov V. S., Lyashev Y. D. (2015). Effects of melatonin on stress-induced changes in the liver of rats with different resistance to stressBull. Exp. Biol. Med. 159 (3), 314–317. 10.1007/s10517-015-2950-5 [PubMed] [CrossRef[]
  • Smith M., Edwards R., McCann U., Haythornthwaite J. (2007). The Effects of sleep deprivation on pain inhibition and spontaneous pain in womenSleep Deprivation Pain Woman. 30 (4), 494–505. 10.1093/sleep/30.4.494 [PubMed] [CrossRef[]
  • Sorci G., Bianchi R., Riuzzi F., Tubaro C., Arcuri C., Giambanco I., et al. (2010). S100B protein, a damage-associated molecular pattern protein in the brain and heart, and beyondCardiovasc Psychiatry Neurol 2010, 656481. 10.1155/2010/656481 [PMC free article] [PubMed] [CrossRef[]
  • Thelin E. P., Nelson D. W., Bellander B. M. (2017). A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injuryActa Neurochir (Wien). 159 (2), 209–225. 10.1007/s00701-016-3046-3 [PMC free article] [PubMed] [CrossRef[]
  • Vidor L. P., Torres I. L., Custódiode Souza I. C., Fregni F., Caumo W. (2013). Analgesic and Sedative Effects of Melatonin in Temporomandibular Disorders: A Double-Blind, Randomized, Parallel-Group, Placebo-Controlled StudyJournal Pain Symptom Management. 46 (3), 422–432. 10.1016/j.jpainsymman.2012.08.019 [PubMed] [CrossRef[]
  • Villapol S., Fau S., Renolleau S., Biran V., Charriaut-Marlangue C., Baud O. (2011). Melatonin promotes myelination by decreasing white matter inflammation after neonatal strokePediatr. Res. 69 (1), 51–55. 10.1203/PDR.0b013e3181fcb40b [PubMed] [CrossRef[]
  • Wang X., Ratnam J., Zou B., England P. M., Basbaum A. I. (2009). TrkB signaling is required for both the induction and maitenance of tissue and nerve injury-induced persistent painJ. Neurosci. 29 (17), 5508–5515. 10.1523/JNEUROSCI.4288-08.2009 [PMC free article] [PubMed] [CrossRef[]
  • Warmenhoven F., Van Rijswijk E., Engels Y., Kan C., Prins J., Van Weel C., et al. (2012). The Beck Depression Inventory (BDI-II) and a single screening question as screening tools for depressive disorder in Dutch advanced cancer patientsSupport Care Cancer 20 (2), 319–324. 10.1007/s00520-010-1082-8 [PMC free article] [PubMed] [CrossRef[]
  • Whitehead K. J., Rose S., Jenner P. (2004). Halothane anesthesia affects NMDA-stimulated cholinergic and GABAergic modulation of striatal dopamine efflux and metabolism in the rat in vivoNeurochem. Res. 29 (4), 835–842. 10.1023/B:NERE.0000018858.64265.e9 [PubMed] [CrossRef[]
  • Yon J. H., Lisa B., Carter R. J., Reiter V. J-T. (2006). Melatonin reduces the severity of anesthesia-induced apoptotic neurodegeneration in the developing rat brainNeurobiology Disease. 21 (3), 522–530. 10.1016/j.nbd.2005.08.011 [PubMed] [CrossRef[]
  • Yu H., Chen Z. Y. (2011). The role of BDNF in depression on the basis of its location in the neural circuitryActa Pharmacol Sin. 32 (1), 3–11. 10.1038/aps.2010.184 [PMC free article] [PubMed] [CrossRef[]
  • Zanette S. A., Dussan-Sarria J. A., Souza A., Deitos A., Torres I. L. S., Caumo W. (2014). Higher serum S100B and BDNF levels are correlated with a lower pressure-pain threshold in fibromyalgiaMol. Pain. 10 (1), 1–9. 10.1186/1744-8069-10-46 [PMC free article] [PubMed] [CrossRef[]
  • Zhang H. M., Zhang Y. (2014). Melatonin: a well-documented antioxidant with conditional pro-oxidant actionsJ. Pineal Res. 57 (2), 131–146. 10.1111/jpi.12162 [PubMed] [CrossRef[]
  • Zhang J., Yao W., Hashimoto K. (2016). Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic TargetsCurr. Neuropharmacol. 14 (7), 721–731. 10.2174/1570159X14666160119094646 [PMC free article] [PubMed] [CrossRef[]
  • Zhou D., Zhang Z., Liu L., Li C., Li M., Yu H., et al. (2017). The antidepressant-like effects of biperiden may involve BDNF/TrkB signaling-mediated BICC1 expression in the hippocampus and prefrontal cortex of micePharmacol Biochem. Behav. 157, 47–57. 10.1016/j.pbb.2017.02.004 [PubMed] [CrossRef[]

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

Plaats een reactie ...

Reageer op "Melatonine vermindert pijn bij patienten met borstkanker die chemo krijgen en vermindert ontstaan depressieve symptomen na operatie van borstkanker"


Gerelateerde artikelen